TNGX · Tango Therapeutics, Inc.
$23.51
-1.69 (-6.71%)
At close · Aug 20
Market Cap
$3.92B
Shares
168.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.51
Open$25.51
Day$23.15–25.67
52W close$6.36–32.90
Avg vol 30d2.3M
Short int44.6M · 26.5% float · 19.2d
Short vol63%
DataSep 2020–Aug 2026
Filing10-Q · Aug 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
−18%
below
RSI (14)
34
neutral
MACD trend
Negative
52-week position
65%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
+111%
trailing
YTD return
+165%
this year
Relative strength
+100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $29 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +78 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.46% of float · ▲ +4.4% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
247 holders — near 3-yr high, broad support
Squeeze score
76
high risk · 0–100
Fundamentals
Revenue growth
+48%
Y/Y
EPS growth
+27%
Y/Y
Free cash flow
$-139.9M
Balance sheet
$112.3M
net cash
Quant / Vol
risk profile
Volatility
101%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
−18%
Bearish
RSI (14)
34
Neutral
MACD trend
Negative
Bearish
52-week position
65%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $29 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+27% holders QoQ · +78 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
26.46% of float · ▲ +4.4% MoM · 19.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
247 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $24 · 65%
Range high $33
vs 200-day avg +25%
vs 50-day avg -18%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNGX
this stock
Tango Therapeutics, Inc.
|
$3.92B | +165.3% | +48.3% | — | 26.5% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNGX | -8.3% | -14.4% | +111.0% | -13.5% | +165.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -6.4% | -17.7% | +99.9% | -15.6% | +153.5% |
Key facts
CIK
1819133
CUSIP
87583X109
13F (30d)
241 filings
238 filers
Visit website
Investor relations